News
🌏 Asia-PacificLatest pharmaceutical news, drug approvals, and NMPA regulatory updates
Latest News
Claruvis Pharmaceutical's Retoxin Becomes World's First Approved Recombinant Botulinum Toxin Type A in China
China's NMPA approves Retoxin, the world's first recombinant botulinum toxin type A, marking a technological breakthrough in aesthetic medicine treatments.
Jyong Biotech Advances Market Access Strategy for Botanical Drug Botreso® and PCP Pipeline
Jyong Biotech (NASDAQ: MENS) updates market access strategies for botanical drugs Botreso® and PCP, establishing competitive advantages in plant-derived therapeutics.
Arcera Life Sciences Partners with Fosun Pharma for Neurodegenerative Disease R&D Collaboration
Arcera Life Sciences and Fosun Pharma establish strategic framework for neurodegenerative disease research, licensing, and technology development.
Samsung Bioepis Partners with ATLATL Innovation Center to Accelerate Asia-Pacific Biotech Development
Samsung Bioepis and ATLATL Innovation Center sign MoU to accelerate early-stage biotech innovation across Asia-Pacific region through open collaboration.
TGA Updates Comprehensive Regulatory Framework for Implantable Medical Devices in Australia
Australia's TGA provides updated guidance on implantable medical device regulations, covering manufacturing, application processes, and market authorization requirements.
Immunic Appoints Dr. Michael Panzara as Chief Medical Officer to Lead Vidofludimus Calcium Development
Immunic Inc. names multiple sclerosis drug development expert Dr. Michael Panzara as CMO to advance Vidofludimus Calcium through pivotal trials.
Zhengye Biotechnology Reports Fiscal 2025 Financial Results for Veterinary Vaccine Business
Zhengye Biotechnology (NASDAQ: ZYBT) announces fiscal year 2025 financial results, highlighting performance in veterinary vaccine manufacturing and research operations.
ChinaBio Partnering Forum: Biotech Investment Trends Emerge
The ChinaBio® Partnering Forum convened industry leaders to assess biotech investment trends and partnership opportunities across Asia-Pacific. Regulatory reforms, emerging technologies, and strategic cross-border collaborations are reshaping the investment landscape.
Akso Health Group Launches Brain-Computer Interface R&D Program Targeting Neurotechnology Market
Akso Health Group (NASDAQ: AHG) announces entry into brain-computer interface development, establishing R&D infrastructure for next-generation neurotechnology solutions.
Evofem Biosciences Secures Exclusive SOLOSEC Distribution Agreement for Sub-Saharan Africa Market
Evofem Biosciences announces exclusive distribution deal for SOLOSEC (secnidazole) in Sub-Saharan Africa, expanding access to FDA-approved treatment.
PSG 2026 Specialty Drug Benefits Report: Cost Management Remains Top Priority as Coverage Strategies Challenge Payers
PSG's 13th annual report reveals payers prioritize cost management while struggling with coverage strategies for new specialty drugs and indications.
WuXi AppTec Reports 39.4% Revenue Growth in Q1 2026, Backlog Reaches RMB 59.77 Billion
WuXi AppTec delivers strong Q1 2026 results with 39.4% revenue growth and 71.7% profit increase, signaling robust pharmaceutical outsourcing demand.
IMG Pharma Acquires Matsumoto Pharmaceutical in Strategic Japanese Market Expansion Deal
IMG Pharmaceutical announces definitive agreement to acquire Matsumoto Pharmaceutical, expanding its presence in Japan's pharmaceutical manufacturing market.
Aquestive Therapeutics Faces Class Action Lawsuit Over Anaphylm Drug Approval Timeline Claims
Investors file class action against Aquestive Therapeutics alleging misleading statements about Anaphylm sublingual film approval timeline and January 2026 PDUFA date.
BioMarin Completes $3 Billion Acquisition of Amicus Therapeutics, Expands Rare Disease Portfolio with Galafold and Pompe Therapies
BioMarin's acquisition of Amicus adds globally approved Galafold for Fabry disease and POMBILITI/OPFOLDA combination for Pompe disease to its rare disease pipeline.
Eyebright Medical Reports Strong 2025 Results Driven by Innovation and Global Expansion
Eyebright Medical Technology releases 2025 annual and sustainability reports showing strong performance amid industry policy adjustments and global expansion.
PMDA Advances Japanese Pharmacopoeia and Medical Device Standards Development Through Enhanced Regulatory Science Framework
Japan's PMDA strengthens pharmaceutical and medical device standards through expanded regulatory science initiatives and Japanese Pharmacopoeia updates.
PMC Organometallix Announces 10-25% Price Increases Across All Product Lines Effective May 2026
PMC Organometallix will implement 10-25% price increases on all products globally starting May 1, 2026, citing significant market condition changes.
Australia's TGA Updates Personalised Medical Device Regulations: New Guidance for Market Authorization and Supply Chain Compliance
Australia's TGA releases comprehensive regulatory guidance for personalised medical devices, covering application processes, market authorization, and supply chain requirements.
Sunnybrook Health Sciences Centre Receives $41 Million Investment to Expand Clinical Trials Infrastructure in Canada
Sunnybrook Health Sciences Centre announces $41M philanthropic investment to expand clinical trials capacity and strengthen Canada's position in global research.